WO2007033078A2 - Reactifs de banque de sang marques a l'aide de particules magnetiques et techniques associees - Google Patents

Reactifs de banque de sang marques a l'aide de particules magnetiques et techniques associees Download PDF

Info

Publication number
WO2007033078A2
WO2007033078A2 PCT/US2006/035309 US2006035309W WO2007033078A2 WO 2007033078 A2 WO2007033078 A2 WO 2007033078A2 US 2006035309 W US2006035309 W US 2006035309W WO 2007033078 A2 WO2007033078 A2 WO 2007033078A2
Authority
WO
WIPO (PCT)
Prior art keywords
complex
antibody
magnetic
ahg
antigen
Prior art date
Application number
PCT/US2006/035309
Other languages
English (en)
Other versions
WO2007033078A3 (fr
Inventor
Henry A. Graham
John G. Gorman
James P. Rowell
Original Assignee
Chrome Red Technologies, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chrome Red Technologies, Llc filed Critical Chrome Red Technologies, Llc
Publication of WO2007033078A2 publication Critical patent/WO2007033078A2/fr
Publication of WO2007033078A3 publication Critical patent/WO2007033078A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/80—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54326—Magnetic particles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances

Definitions

  • This invention relates to blood banking immunological diagnostic testing and immunohematology and more particularly to blood cell serological testing using magnetic particles and magnets to separate bound entities to be measured from unbound entities. It also relates to the use of chromatographic media and liquid phase media in such measurements. It further relates to determination of antigens, antibodies and other proteins on blood cells, in serum and other bodily samples and the use of buffers and other fluids in the determination process.
  • the DIRECT COOMBS (Antiglobulin') TEST The direct Coombs (antiglobulin) test, which is used in the investigation of anemias, will demonstrate whether red blood cells are coated with incomplete antibody, especially that of babies born to Rh-negative mothers. It will reveal whether antibodies have been adsorbed on the surface of the red cells while the baby was in the uterus and is important in diagnosing Rh hemolytic disease of the newborn.
  • the direct Coombs (antiglobulin) test is performed by washing the red blood cells to be tested and attempting to agglutinate them with Coombs (antiglobulin) reagent. The Coombs reagent is widely available.
  • Coombs test As well as the indirect test described below, are variously referred to herein as Coombs test, anti-globulin test, AHG test or variations thereof.
  • the serum is variously referred to as Coombs serum, anti- human globulin serum, AHG serum or the like.
  • Group O reagent antibody screening cells are available commercially. They are a group of two or three O Rh positive and Rh negative donor red blood cells selected so as to be positive on at least 50% of the cells for each of the common clinically important red blood cell antigens. If a serum gives a positive reaction with such screening cells, tested separately or as a mixture, it must contain an atypical antibody of unknown identity.
  • the techniques involved in performing the direct and indirect antiglobulin and the reasons therefore, are well-known in the art.
  • ABO GROUPING Red cell (forward) typing with anti-A or anti-B reagents will demonstrate the presence or absence of A and B antigens on the red cell. Serum (reverse) typing with reagent A and B red cells will demonstrate the presence of anti-A and anti-B in the serum.
  • OTHER REAGENTS USEFUL IN ABO GROUPING Other reagents may be used routinely in ABO grouping. They are often essential for resolving discrepancies between forward and reverse typing. Blood is not usually released from the blood bank for transfusion until any such discrepancies have been resolved. Anti-A, B (Group O serum) can detect weak A variants that may be missed by regular anti-A reagent.
  • Anti-A Anti-A
  • B reagent Group O serum
  • Anti-Ai reagent absorbed B serum or Dolichos lectin
  • Anti-H lectin Ulex
  • Reagent O Rh-positive screening cells Reagent A 2 cells
  • COMPATIBILITY TESTING Crossmatch (compatibility) tests are performed to determine the suitability of the donor's blood for the particular recipient. Blood transfusions are not given before performing a major crossmatch to test the donor's red cells against the serum of the recipient. If both donor and recipient are of the same blood group, a minor cross- match may be done to test the recipient's red cells against the donor's serum. The minor crossmatch is of no value when donor and recipient belong to different blood groups because agglutination will occur .
  • Major Crossmatch involves mixing donor's red cells with recipient's serum, centrifuging at 37 0 C and adding antiglobulin reagent.
  • Minor Crossmatch involves mixing donor's serum with recipient's red cells, centrifuging at 37° C and adding antiglobulin reagent.
  • RH TYPING The crossmatch makes it possible to avoid hemolytic transfusion reactions following a particular transfusion.
  • Blood banks are also concerned about isosensitization. If, for example, a blood bank selects Rho (D)-positive blood for an Rho (D)-negative woman, she will not have an incompatible crossmatch or a transfusion reaction if she has no anti-Rho (D) antibodies in her blood, but she may become sensitized to the Rho (D) antigen. Initiation of the immune response presents problems for subsequent transfusions and for subsequent pregnancies if she has an Rho (D) -positive mate.
  • Rho (D) negative donors, Rho (D)-negative women and their Rho (D)-negative mates, and Rho (D)-negative cord bloods are tested for the presence of Rho ⁇ variant (DU) antigen that may not always be detected by the anti-Rho (D) slide test.
  • Various Rh typing methods and the appropriate controls are well known to the art.
  • ANTIBODY TESTS Screening for antibodies is especially important for patients receiving blood and the obstetrical patient. In obstetrical patients, early detection allows time to prepare for possible intrauterine or exchange transfusion in cases of Rh hemolytic disease of the newborn. Once the presence of an antibody has been detected, the problem of its identification remains, but this has been simplified by the development of antibody identification panels of group O reagent red cells. These screening and identification methods are well known to those skilled in the art.
  • the foregoing tests and other similar tests are traditional and conventional and performed routinely in the blood banking field.
  • the present invention is useful in performing virtually all of such tests that are performed in the blood bank involving reactions between binding partners such as immunological binding partners or universal binding partners such as lectins, biotin-avidin, Protein A or G, ligands and their receptors and the like.
  • magnets and magnetic particle-labeled reagents are used to capture and/or release magnetic particle-tagged entities for immunohematology diagnostic testing purposes.
  • the magnetic tagged entities may be, depending on the particular assay, any of tagged antibodies, tagged blood cells, tagged universal binding partners, especially red blood cells, binding agents such as lectins, biotin-avidin, Protein A or G, ligands and their receptors and the like.
  • the invention utilizes magnetic particles directly labeled with antibody (such as anti-A, anti-B, anti-D or anti-human serum).
  • antibody such as anti-A, anti-B, anti-D or anti-human serum.
  • the red cells will only react with magnets if the red cells have the reactive antigen corresponding to the specific antibody on them (and in the case of anti-human serum have been washed clean of serum).
  • the presence of an RBC on a magnet is a positive event for the presence of the antigen sought and can be seen because of the hemoglobin in the cells.
  • Another reagent used in the invention are magnetic particles labeled with a red cell binding partner, i.e., a lectin or other universal red blood cell binding material (in effect an anti-RBC).
  • a red cell binding partner i.e., a lectin or other universal red blood cell binding material (in effect an anti-RBC).
  • the lectin or other binding molecule should be able to bind magnetic particles to all human red blood cells regardless of blood group, and must not react with Coombs serum or other human antibodies.
  • the magnetic particles are used to move the RBCs through zones or are positioned at a location on a chromatographic strip so that fluids can move by the cells (i.e., the fluids move over the comparatively stationary cells).
  • a labeled AHG reagent not bound to a magnet, but labeled with a detectable indicator such as an enzyme, fluorophor, and the like, described in more detail below, is used to react with the magnet bound red cell complex and any bound serum antibody.
  • a detectable indicator such as an enzyme, fluorophor, and the like, described in more detail below
  • An essential part of the invention in one of its aspects is to provide for separation of unbound material from bound material, wherein the separation is effected through the combined use of the magnetic field effect on the magnetic labeled reactant and the density gradients of layers in the path of flow of reagents. This is especially true of any test that utilizes the Coombs (anti-globulin reagent).
  • the invention in another of its aspects provides a chromatographic lateral flow format with an end point determination that does not require centrifugation to detect reacted entities. Virtually all current blood bank diagnostic tests require centrifugation at some point.
  • a liquid format is employed wherein the bound magnetic reagents are pulled through liquid layers of varying density gradient layers via magnetic field effect while the unlabeled material remains in a liquid phase of lower density.
  • the invention also may employ software to sense the progress of process to provide feedback to timing of incubation, reagent dispensing, order, amount of reagent dispensing, application or removal of magnetic field and the like.
  • the present invention provides novel reagents tagged with magnetic particles, first among which is anti-human globulin (AHG) (Coombs) reagent, tagged with magnetic particles.
  • AHG anti-human globulin
  • Red cells that react with this reagent by forming a complex with the AHG will be captured by the magnetic field of the invention.
  • This "capture" will be an indication of the presence of antibodies bound to antigens on the surface of blood cells, such as red blood cells, white blood cells, platelets, and the like.
  • the invention also provides for novel magnetic particle tagged blood cell antibody reagents such as anti-A, anti-B, anti-D, anti-K etc and novel magnetic particle tagged blood cells, reagents such as the A and B antigens and red blood cells.
  • These reagents comprise the usual blood typing reagents of various specificities as used in blood bank laboratories but tagged with magnetic particles or beads, so that red cells (or any other blood cells) coated with the antibody reagents and sample antibody coated onto tagged reagent red cells will be captured by the magnetic field of the invention and thus indicate the presence of the specific antigens on the blood cell surface corresponding to the specific antibody of the tagged particle complex.
  • novel magnetic tagged reagents comprising entities such as lectins, non-immunological binding pairs and universal binding agents which will bind to all blood cells, regardless of blood type, may also be produced.
  • Such blood cells preferably, red blood cells, coated with these reagents by reaction therewith will be captured by the magnetic field of the invention and may be held stationary for reading or for further processing in the test such as washing, concentration, prolonging and enhancing antibody incubation etc. If the magnetic field is removed, the cells will continue to flow according to the individual test protocol.
  • indicator labels such as enzymes and their substrates, fluorophors, chemiluminescent materials, radioactive isotopes, and other labels may be attached to the appropriate reagents, especially to non-magnetic tagged anti-human globulin, and analyte proteins in the manner well-known in the immunoassay art and thus serve to act as the element by which the progress and results of the test may be observed and measured during the test run.
  • the magnetic reagents can be prepared by methods well-known in the art. Magnetic particles attached to proteins have been made in the art and are well- known. Their process of preparation is well-known. When such labels are used in the method of the invention as a means to visualize the end point, suitable substrates or exciting media should be supplied at appropriate places in the assay construct.
  • the magnets can be configured in various patterns to re-footprint flowing antibodies, red cells and reagents.
  • the patterns could be alphabetic letters or words, circles, straight lines or artistic patterns of magnetic dots or other patterns such as indentations in the magnet surface to create a very recognizable picture of blood cell capture like a lithograph. Detection of the captured magnetic entity can be aided by computer algorithms for pattern recognition, if desired.
  • Magnetic strengths across the magnetic footprint can be varied allowing measurement of the strength of reaction and quantitation of antibodies by measuring how far migration takes place in an increasing magnetic field. This enables further fine separation of reactants.
  • the use of magnets with gaps in the magnetic field so that some of the magnetic decorated blood cells can flow past through the gaps to be captured further onto the magnet to make a recognizable footprint pattern or for supplementary processing further along the chromatographic medium is also an aspect of the invention.
  • Software can be developed to process the video or still image of multiple test runs, to segregate tests being run in parallel or otherwise closely juxtaposed areas of chromatographic media. This technology is art-known for pattern recognition for monitoring flow, archiving test run images and interpretive data, processing and presenting clinical and workflow data generated in test runs.
  • a mixture of reagent red blood cells, patient anti-serum and magnetic particle tagged lectin is prepared and allowed to incubate in a suitable assay construct. During the incubation, any antibody reactable with reagent red blood cells will react to result in a RBC coated with antibody. The magnetic lectin will react with the red blood cell since it is a universal RBC reactant. A magnetic field is applied to the reacted mixture (the complex) which is pulled by the magnetic field through a liquid zone in the strip and washed in that zone.
  • AHG antihuman globulin
  • a detection label such as an enzyme, fluorophor, chemiluminescent material, radioactive isotope or the like.
  • AHG antihuman globulin
  • the AHG combines with the antibody of the complex thus attaching a readable label to the magnetic complex. Separation of unreacted AHG from the magnetic complex is achieved by drawing the complex through liquid zones of increasing density, so that lighter unreacted labeled AHG will remain in the lower density regions and will not take part in the reading determination.
  • the reading of the labeled AHG is facilitated by providing a suitable substrate for the label at the reading zone of the assay construct.
  • magnetized coated, reacted RBCs can be stopped on the magnet and immobilized as described above.
  • Driving fluids or buffer solutions can be introduced onto the strip and allowed to flow by capillary action across the immobilized magnetic complex. This will separate the unbound labeled AHG from the bound labeled AHG and thus eliminate the possibility of unreacted AHG entering into the reading step.
  • the foregoing enables a single Mag reagent for red cell phenotyping including forward ABO typing.
  • the magnetic particle lectin anti-RBC or magnetic particle RBC binding partner reagent described above enables a method for performing all blood serology tests with the single magnetic labeled antiglobulin reagent, and using only regular non-Mag reagents in addition. This eliminates the need to develop a whole series of magnetic reagents of different specificities in the preferred embodiment. This method allows all blood bank red cell test to be done with a single magnetic particle reagent and a labeled anti-globulin reagent.
  • Signal acquisition may be achieved by methods normally used in the art in addition to visual observation of accumulated red blood cells or scanning the test construct or viewing the construct with a CCD video camera with appropriate pixel processing software. Interpretation of streaming color patterns could also provide an analyte measure.
  • Separation of proteins from RBC by sedimentation in chromatographic strip media may be based upon differential specific gravity of RBC and proteins and selection of differing specific gravities or densities of the medium as will be described below.
  • different gradients may be supplied by varying the density of layers of the chromatographic strip.
  • any membranes used in the art of immunoassay may be employed as long as it does not non-specifically bind to the red cells or the magnetic particles or can be treated to remove non-specific binding characteristics.
  • typically used in the field are nitrocellulose, filter paper, fiberglass and the like.
  • porosities of greater than about 20 microns are preferred to allow the antibody complexed tagged RBC to settle (or be forced by the magnetic field) into the lowermost layer of the strip, as well be seen below.
  • MAG tagged reagent antibodies could be introduced with the red cells over the magnet and capture red cells coated with cognate antigen.
  • MAG-Coombs serum lying on the magnet will capture coated red cells as they flow past. Non-coated will not be captured.
  • the magnetic particles are coated with typing antibodies or antiglobulin reagent
  • the simplest and easiest way to measure the presence and quantity of red cells bound to the magnetic reagents either in flow or stopped on a magnet is a densitometer scan reading through hemoglobin wavelength filter.
  • An alternative is a CCD color camera with pixel assessing software.
  • chemical amplification of the hemoglobin signal using a chromagen e.g. tetramethyl benzidine (TMB) chromagen/substrate solution would be worthwhile.
  • Enzyme amplification is another method of use. Often, visual observation is suitable for qualitative determination
  • MAG tagged reagent red cells could be introduced just before or over the magnet and held waiting to capture cognate antibody(s).
  • the MAG tagged reagent red cells are introduced in front of the flowing antibody because they flow more slowly when they are retarded by the magnetic field and will bind faster flowing cognate antibody(s) coming past them.
  • the flow or movement of red cells tagged with magnetic particles and serum antibodies analytes of a specimen flow at very different rates in a chromatographic medium in the presence of a magnetic field, it becomes the ideal way to separate them for testing them individually. No preparative centrifugation is necessary, the red blood cells being held in place as materials are removed or added by capillary flow.
  • METHODS FOR QUANTIFYING A POSITIVE CROSSMATCH RESULT A measurement of all cells present in the antiglobulin test phase compared to the number of positive cells collected on the magnet will allow the calculation of the number of units that are reactive with a patient's serum during a pooled crossmatch. This information will provide the technologist with critical information relative to the choice of reflex testing to efficiently find compatible blood for the patient. Using algorithms similar to those used when screening pools of up to 50 plasma donors for infectious disease markers, donor blood can be tested in smaller pools to determine which units are actually incompatible with the donor without cross-matching all of them, saving time, labor and materials.
  • a device useful in the invention may be a chromatographic strip or may represent layers of liquids of different densities, in for example, a microtitre plate well. Because of the large number and great variety of combinations and permutations of reactants and reaction schemes, the device is presented in connection with particular reference to the procedural aspects of the device. Those skilled in the art will easily be able to adapt the construct to whatever assay they desire to perform.
  • n, m and p are zero or an integer designating that such zones may or may not be present.
  • the device comprises however, a plurality, i.e. at least two layers of different density.
  • Magnetic-AHG magnetic particle tagged anti-human globulin
  • Zone 1 Add sample or saline control to Zone 1. Sample depends on the specific test,being performed, i.e. direct Coombs, antibody screening, crossmatch, red cell typing or the like.
  • a driving solution such as a buffer.
  • the sample such as RBCs, antibody, and a magnetically tagged universal RBC reactant, such as a lectin, i.e., Mag-lectin, in Zone 1.
  • MAGNET COATED WITH LECTIN TANTI-RBC EXAMPLE: For detection of specific antibodies in patient's serum, for example detection of A,B antigens or O cells and Anti-A, Anti-B, Anti-AB respectively, the test is run in the same way antibody screening is performed. In either case, the reactants in the form of the magnetically tagged reagent cells or reagent antibodies are added directly onto Zone 1 and allowed to react therein and then pass into other Zones of higher density. Labeled anti-human globulin present in a lower zone is used to label any reacted complex for detection.
  • the invention also applies to systems using antibody coated magnetic particles and magnets, to be applied to multiplexing cross-matching of many donors with patient serum in one reaction vessel, to antibody screening with multiple cells, to detecting fetal red blood cells in a sample of maternal blood and other applications where it is desirable to detect the presence of a minor population of red blood cells from another individual in a blood sample.
  • the novel magnetic particle method can be applied to straight blood typing of single individual patients and donors, and to other blood cell serological (immunohematology) testing.
  • a vessel or an array of vessels such as a microtiter plate, or other segregated localized area or volume in other media, is provided that is designed to allow the red blood cells of the test sample to be contacted with a test solution having activated magnetic particles, which will attach to the test red blood cells that react with the test solution but not to test red blood cells that do not react with the solution.
  • a magnetic field generated by a magnet or electromagnet, is selectively applied to the medium, which causes the red blood cells to be held in a manner allowing the red blood cells not decorated with magnetic particles to be removed or allowing the red blood cells held by the magnetic field to be removed.
  • the red blood cells held by the magnetic field are re-suspended and quantitated spectrophotometrically. Enzyme amplification of the signal may be employed to increase sensitivity.
  • the magnetic field is applied at the underside of a microplate in which the test solution is added to the mother's red blood cell suspension.
  • the degree of magnetic force applied to the membrane may be selectively adjusted to vary the width or surface area of the capture line or zone.
  • METHODS FOR DETECTING AND QUANTIFYING FMH IN RH NEGATIVE MOTHERS Because of the great sensitivity of the magnetic method, the general method can be specifically adapted to detect and quantitate fetal red cells in maternal blood, including blood samples from Rh-negative mothers. During pregnancy the blood circulations of mother and baby are separate and do not mix. However, harmless leakage of small amounts of blood from the baby's circulation into the mother's circulation is usual in almost every pregnancy. This is called Fetal Maternal Hemorrhage (FMH). Diagnostic tests to detect and measure the amount of baby's blood in the mother's blood sample are very important in the case of an Rh Negative mother pregnant with an Rh Positive baby.
  • FMH Fetal Maternal Hemorrhage
  • RhoGAM® Ortho Pharmaceutical Co. Raritan, New Jersey
  • Rh Negative mothers at time of risk of Rh immunization, which is late pregnancy and delivery when FMH regularly occurs.
  • RhoGAM which covers FMH up to 15ml
  • One dose of RhoGAM which covers FMH up to 15ml, is given at 28 weeks gestation to all Rh negative mothers and another dose after delivery if the baby is Rh-positive.
  • FMH a large and even massive FMH, which must be detected and measured because in that case multiple doses of RhoGAM are necessary to prevent Rh immunization.
  • the current screening test is a commercially available kit which employs mixed field detection in which any baby's red blood cells in the mother's blood sample form "rosettes" which are seen under the microscope and counted by a technologist.
  • the currently used quantitative test for fetal RBC in mother's blood is used when the screening test is positive. It is sensitive to less than 0.1 ml of fetal cells in the mother's circulation and is quantitative.
  • Kleihauer-Betke test is not a satisfactory test because it is manual, time consuming, requires skill and care, involves a technician training and competency assessment burden, uses unstable unpredictable reagents, is prone to false positive and false negative results and is very imprecise.
  • the novel FMH method of the invention is simple, provides objective quantitative data and is easily adapted for automation.
  • specific antibody reagent tagged with magnetic particles is applied in a liquid medium to a red blood cell sample in a vessel that contains presumably a minor population(s) of red cells from a different individual.
  • the magnetically tagged antibodies bind to red blood cells that carry the chosen specific antigen on their surface, thus attaching magnetic particles to the red cell surface of antigen positive cells (of the minor population) but not to antigen negative cells (of the patient).
  • Reagent magnetic antibody is carefully chosen to react with the minor population of red cells that is to be detected and measured so only the minor population of cells would be decorated with magnetic particles.
  • a magnetic field is then applied and draws the tagged cells to the inside surface of the vessel directly, or through a separate zone of higher density to separate the unbound cells from the magnet tagged cells, or other solid state and immobilizes them there. This is possible where different blood groups can be identified on the transfused red blood cells but not on the patient's red blood cells.
  • the magnetic particle test kit procedure would be as follows: incubate maternal blood with anti-D coated magnetic particles, apply magnetic field, remove free red blood cells physically or by separating them in a separate zone, pipette color developer reagent which would hemolyse residual fetal RBC and develop color. Read OD in capture zone using colorimeter. This procedure is done with a sample of blood collected from an Rh negative mother that has delivered an Rh positive baby.
  • the key reagent is a suspension of magnetic particles (iron) that are coated with anti-D antibodies. These may be prepared by techniques well-known in the art. The concentration of the magnetic particles and mother's blood used in the assay will be important and need to be standardized, but in general there should be an excess of magnetic particles to the expected maximum fetal cells in the assay.
  • a preferred embodiment is to incubate mother's blood sample with magnetic anti- Rh reagent and start flow towards the magnet. If a "minor population" of Rh-positive fetal red cells were present in the mother's blood sample they will be captured by the magnet and the mother's Rh negative red cells will flow on past the magnet. The fetal cells are quantitated by measuring the amount or proportion of red cells stopped on magnet.
  • a magnetic force field pulls the magnetic particles and any red cells attached to the through the denser zone and to the portion of the device where these magnetic bound cells can be quantitated. It is simple to compare the number of separated magnetic tagged cells to the total number of cells or the untagged cells. [0058] Besides the test for FMH, there are other blood bank laboratory and forensic laboratory applications where it is important to detect the presence of a minor population of red blood cells from a second individual in a sample of blood belonging to the first individual, such as athlete blood doping.
  • This test is valuable in assaying the survival of transfused blood from various donors, in the biological compatibility test, multiplexing cross-matching of many donors with a patient(s) in one reaction vessel, antibody screening with multiple cells, research investigation of rare red blood cell chimeras and other special situations, in addition to detecting fetal red blood cells in a sample of maternal blood from an Rh Negative mother.
  • the specific gravity of the uppermost layer of serum addition should be equal to or greater than the specific gravity of serum and the specific gravity of the soluble materials in the sample reaction mixture.
  • the specific gravity of the soluble materials may decrease slightly helping to keep the layer with the sample in place at the top. Reaction products will drop to the layers of like densities. Subsequent lower zones have a specific gravity higher than the upper zone.
  • This general method can be applied to all of the clinical situations listed above where a need for detection and quantitation of a mixed field of red blood cells in a sample is required. Finally the method is applicable to performing blood typing and detection of anti-red cell antibodies on the blood of a single individual where no mixture exists.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention concerne l'utilisation d'aimants et de réactifs marqués à l'aide de particules magnétiques pour la capture et/ou la libération d'entités marquées à l'aide de particules magnétiques dans des analyses diagnostiques immunohématologiques, en particulier des analyses réalisées dans le domaine de la création de banques de sang. Les entités marquées à l'aide de particules magnétiques peuvent être des anticorps marqués, des cellules sanguines marquées, des partenaires de liaison universels marqués, en particulier des lectines marquées et des réactifs de Coombs marqués, ainsi que d'autres agents de liaison, tels que la biotine-avidine, la protéine A ou G, des ligands et leurs récepteurs et analogue. La séparation de matériel non lié par rapport à du matériel lié est obtenue à l'aide d'effets de champs magnétiques sur les réactifs marqués à l'aide de particules magnétiques et/ou de gradients de densité des couches d'un complexe d'analyse. L'invention concerne également un format d'immunochromatographie sur membrane et des réactions en phase liquide dans des récipients adaptés, permettant de déterminer des points finaux et de détecter des entités ayant réagi, sans étape de centrifugation. Des marqueurs lisibles, tels que des enzymes, des fluorophores, des matières chimiluminescentes, des isotopes radioactifs, et d'autres marqueurs, peuvent être fixés au réactif de Coombs pour obtenir un produit lisible comportant le réactif de Coombs et un anticorps participant à l'analyse.
PCT/US2006/035309 2005-09-13 2006-09-11 Reactifs de banque de sang marques a l'aide de particules magnetiques et techniques associees WO2007033078A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71659105P 2005-09-13 2005-09-13
US60/716,591 2005-09-13

Publications (2)

Publication Number Publication Date
WO2007033078A2 true WO2007033078A2 (fr) 2007-03-22
WO2007033078A3 WO2007033078A3 (fr) 2007-10-25

Family

ID=37865483

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/035309 WO2007033078A2 (fr) 2005-09-13 2006-09-11 Reactifs de banque de sang marques a l'aide de particules magnetiques et techniques associees

Country Status (1)

Country Link
WO (1) WO2007033078A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2963107A1 (fr) * 2010-07-21 2012-01-27 Diagast Complexe immuno-magnetique et son utilisation pour le groupage/phenotypage erythrocytaire
CN103344772A (zh) * 2013-07-19 2013-10-09 中国科学院苏州生物医学工程技术研究所 Miltenberger血型抗体检测新方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5536644A (en) * 1985-12-20 1996-07-16 Behringwerke Ag Particle separation method

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5536644A (en) * 1985-12-20 1996-07-16 Behringwerke Ag Particle separation method

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2963107A1 (fr) * 2010-07-21 2012-01-27 Diagast Complexe immuno-magnetique et son utilisation pour le groupage/phenotypage erythrocytaire
WO2012010654A3 (fr) * 2010-07-21 2012-03-29 Diagast Complexe immunomagnétique et son utilisation dans le groupage/phénotypage des hématies
CN103344772A (zh) * 2013-07-19 2013-10-09 中国科学院苏州生物医学工程技术研究所 Miltenberger血型抗体检测新方法
CN103344772B (zh) * 2013-07-19 2015-06-24 中国科学院苏州生物医学工程技术研究所 Miltenberger血型抗体检测新方法

Also Published As

Publication number Publication date
WO2007033078A3 (fr) 2007-10-25

Similar Documents

Publication Publication Date Title
US9766256B2 (en) Magnetic particle tagged reagents and techniques
US20070059782A1 (en) Magnetic particle tagged blood bank reagents and techniques
TW297094B (fr)
US5374531A (en) Immunoassay for determination of cells
EP0296724B1 (fr) Essai et dispositif utilisant une membrane non-buvant permettant un courant latéral
US7888053B2 (en) Making encoded ghost cells for multiplexed detection of anti-red cell alloantibodies
MX2007000920A (es) Dispositivo de flujo lateral para la deteccion de patogenos grandes.
JP2002504993A (ja) 磁気応答性試薬を使用する磁気補助結合アッセイ
US20110207151A1 (en) Utilisation de ferrofluides pour le phenotypage sanguin et applications derivees
Fisher Use of the manual polybrene test in the routine hospital laboratory
US9518984B2 (en) Separation, washing and determination of analytes tagged with magnetic particles
US10107811B2 (en) Detection of specific antigens in a population of antigens
WO2007033078A2 (fr) Reactifs de banque de sang marques a l'aide de particules magnetiques et techniques associees
JPH05504828A (ja) 毛管の流れ装置および二重捕捉アツセイ法
JP2010078374A (ja) 抗赤血球抗体の検出方法
US20220252622A1 (en) Single tube preparation comprising a panel of differently labeled cells for serology
Plapp et al. Solid-phase microplates and dipsticks in the blood bank
Gabel Banerj ee
JP2003028861A (ja) ヒトヘモグロビン検出装置

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06790207

Country of ref document: EP

Kind code of ref document: A2